COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLGN gained 0.94%, reflecting a mild positive market reaction. This price movement added approximately $233K to the company's valuation, bringing the market cap to $25M at that time.
Data tracked by StockTitan Argus on the day of publication.
REHOVOT,
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com
Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-2025-third-quarter-financial-results-302618450.html
SOURCE CollPlant